Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence
AM Braden, RV Stankowski, JM Engel… - Current …, 2014 - ingentaconnect.com
Breast cancer is the most common cancer amongst women in the United States and around
the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents …
the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents …
GSTP 1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer
T Miyake, T Nakayama, Y Naoi, N Yamamoto… - Cancer …, 2012 - Wiley Online Library
The purpose of the present study was to investigate the association of glutathione S‐
transferase P 1 (GSTP 1) expression with resistance to neoadjuvant paclitaxel followed by 5 …
transferase P 1 (GSTP 1) expression with resistance to neoadjuvant paclitaxel followed by 5 …
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer
CE Horak, L Pusztai, G Xing, OC Trifan, C Saura… - Clinical Cancer …, 2013 - AACR
Purpose: Predictive biomarkers offer the potential to improve the benefit: risk ratio of a
therapeutic agent. Ixabepilone achieves comparable pathologic complete response (pCR) …
therapeutic agent. Ixabepilone achieves comparable pathologic complete response (pCR) …
Tumor chemosensitivity assays are helpful for personalized cytotoxic treatments in cancer patients
Tumor chemosensitivity assays (TCAs), also known as drug response assays or
individualized tumor response tests, have been gaining attention over the past few decades …
individualized tumor response tests, have been gaining attention over the past few decades …
Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin …
N Oda, K Shimazu, Y Naoi, K Morimoto… - Breast cancer research …, 2012 - Springer
Anti-tumor immunity is thought to play a significant role in chemotherapeutic response of
breast tumors. In the present study, we investigated whether tumor infiltrating FOXP3+ …
breast tumors. In the present study, we investigated whether tumor infiltrating FOXP3+ …
Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis
R Leth-Larsen, MG Terp, AG Christensen, D Elias… - Molecular …, 2012 - Springer
The CD44 hi compartment in human breast cancer is enriched in tumor-initiating cells;
however, the functional heterogeneity within this subpopulation remains poorly defined. We …
however, the functional heterogeneity within this subpopulation remains poorly defined. We …
[HTML][HTML] Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy
N Tominaga, Y Naoi, K Shimazu, T Nakayama… - Annals of oncology, 2012 - Elsevier
Background The aim of this study was to investigate the clinicopathological characteristics of
GATA binding protein 3 (GATA3)-positive breast cancers as well as the association of …
GATA binding protein 3 (GATA3)-positive breast cancers as well as the association of …
[HTML][HTML] Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancer
Y Sota, Y Naoi, R Tsunashima, N Kagara, K Shimazu… - Annals of oncology, 2014 - Elsevier
Background The aim of this study was to construct a novel prediction model for the
pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) using immune …
pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) using immune …
Gene expression–based prediction of neoadjuvant chemotherapy response in early breast cancer: results of the prospective multicenter EXPRESSION trial
K Edlund, K Madjar, A Lebrecht, B Aktas, H Pilch… - Clinical Cancer …, 2021 - AACR
Purpose: Expression-based classifiers to predict pathologic complete response (pCR) after
neoadjuvant chemotherapy (NACT) are not routinely used in the clinic. We aimed to build …
neoadjuvant chemotherapy (NACT) are not routinely used in the clinic. We aimed to build …
The impact of Onco type DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast …
A Soran, R Bhargava, R Johnson, G Ahrendt… - Breast …, 2016 - content.iospress.com
BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in
estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to …
estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to …